Skip to main content

Table 1 Baseline characteristics and antibody titers among patients treated with anti-fibrotic treatment and matched control

From: Humoral response among patients with interstitial lung disease vaccinated with the BNT162b2 SARS-Cov-2 vaccine: a prospective cohort study

  Anti-fibrotic Treatment
(n = 40)
Matched control
(n = 40)
P value
Age, median (IQR), y 71 (67–75) 69 (63–72) 0.02
Male sex (%) 27 (67.5) 16 (40) 0.01
IgG titer, median (IQR), Au/ml 361.10 (207–811) 820.75 (459–1313) 0.001
IgG titer GMT (SD) 441.26 ± 3.15 835.41 ± 2.07 0.004
Seropositive (%) 40 (100) 40 (100) 1.0
Days post vaccination, median (IQR) 173 (168–182) 128.55 (123–142) < 0.001